Clinical Trial: Vitamin D Supplementation After Parathyroid Surgery

Study Status: Active, not recruiting
Recruit Status: Active, not recruiting
Study Type: Interventional

Official Title: Vitamin D Supplementation After Successful Parathyroid Surgery for Primary Hyperparathyroidism

Brief Summary: A randomised double blind clinical trial, accepted by the Medical Products Agency and registered in the European Clinical Trials Database. Aims to evaluate the prevalence of vitamin D deficiency in a pHPT population in relation to gender and age, the correlation between vitamin D status, pre- and postoperative parathyroid hormone level and bone density and the correlation between vitamin D status, metabolic, cardiovascular risk factors and QoL aspects before and after parathyroid adenomectomy.

Detailed Summary: 150 PHPT patients were randomized six weeks after surgery, 75 into each group, to 1 year of oral treatment with either calcium carbonate 1 g (500 mg twice daily) alone or calcium carbonate 1 g combined with cholecalciferol 1600 IU (800 IU twice daily). Exclusion criteria were age under 18, manifest osteoporosis at PHPTdiagnosis, persistent hypercalcemia after surgery, postoperative hypocalcemia requiring vitamin D treatment, glomerular filtration rate (GFR) below 40 ml/min, pregnancy, breast feeding, or logistical difficulties, for example living far from the hospital. Included patients had to withdraw any current supplementation with calcium and vitamin D during the study period. All tablets were identical in appearance, the tins were numbered and randomization followed a list compiled by an independent clinical research support organization. The time for randomization was chosen to make sure that the PHPT patients were cured before starting the study medication. Nearly three-quarters of the patients were randomized within 6 weeks after PTX.The primary end point was the change in PTH after PTX and treatment with the study medication. Secondary end points were vitamin D levels, insulin resistance, blood pressure and other cardiovascular risk factors, biochemical markers of bone turnover, bone mineral density and self estimated health related quality of life (SF- 36).
Sponsor: Karolinska University Hospital

Current Primary Outcome: postoperative parathyroid hormone level [ Time Frame: 3 months ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

  • bone mineral density [ Time Frame: one year ]
  • ambulatory blood pressure [ Time Frame: one year ]
  • 25-OH Vitamin D [ Time Frame: 3 months ]
  • Calcium [ Time Frame: 6 weeks ]
  • Quality of life [ Time Frame: one year ]


Original Secondary Outcome: Same as current

Information By: Karolinska University Hospital

Dates:
Date Received: September 22, 2009
Date Started: April 2008
Date Completion: December 2016
Last Updated: March 11, 2016
Last Verified: March 2016